Treatment/medications
Therapeutic algorithms for children with rhinitis in children are long based on the same principles as in adults [85]. During the past two decades ARIA has proposed an evolving guideline for the management of patients with AR. More recently, intergraded care pathways (ICPs) have been proposed, based on technology-evident information, providing a self-care plan by a multidisciplinary group of health professionals centered around the patient [59]. In specific, an algorithm based on the visual analogue scale (VAS) for assessing rhinitis symptoms has been revised by the ARIA expert group for (1) selection of pharmacotherapy for patients with AR and (2) to tailor treatment depending on control [86].
ARIA has been the first guideline in the field of allergy to have used the GRADE system to formally evaluate and appraise evidence. In its latest update, an important step is the addition or real-life evidence, supported through an mHealth application [59]. Real-life approaches are increasingly used to complement randomized trials, in order to expand the scope and evaluate external validity of the findings [87].
Treatment of AR includes allergen avoidance whenever possible, use of medications and allergen specific immunotherapy (AIT)